{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:59:57Z","timestamp":1767142797803,"version":"build-2238731810"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["NCT02149004"],"award-info":[{"award-number":["NCT02149004"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s15010-018-1248-8","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T01:18:42Z","timestamp":1541726322000},"page":"247-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016"],"prefix":"10.1007","volume":"47","author":[{"name":"ClinSurv Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3460-1299","authenticated-orcid":false,"given":"Melanie","family":"Stecher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schommers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kollan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gunsenheimer-Bartmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Platten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"CJ Murray","year":"2012","unstructured":"Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197\u2013223.","journal-title":"Lancet"},{"key":"1248_CR2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163\u201396.","journal-title":"Lancet"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"The Antiretroviral Therapy Cohort Collaboration","year":"2017","unstructured":"The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349\u2013e56.","journal-title":"Lancet HIV"},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/505147","volume":"194","author":"RP Walensky","year":"2006","unstructured":"Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11\u20139.","journal-title":"J Infect Dis"},{"key":"1248_CR5","first-page":"11","volume":"343","author":"M May","year":"2011","unstructured":"May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. Br Med J. 2011;343:11.","journal-title":"Br Med J"},{"key":"1248_CR6","unstructured":"UNAIDS. Fact sheet\u2014latest statistics on the status of the AIDS epidemic. \n                    http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf\n                    \n                  . Accessed Feb 2018."},{"key":"1248_CR7","volume-title":"90-90-90\u2014an ambitious treatment target to help end the AIDS epidemic","author":"UNAIDS","year":"2014","unstructured":"UNAIDS. 90-90-90\u2014an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations; 2014."},{"key":"1248_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.COH.0000410239.88517.00","volume":"6","author":"R Camacho","year":"2011","unstructured":"Camacho R, Teofilo E. Antiretroviral therapy in treatment-naive patients with HIV infection. Curr Opin HIV AIDS. 2011;6:3\u201311.","journal-title":"Curr Opin HIV AIDS"},{"key":"1248_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/EDE.0000000000000041","volume":"25","author":"ES Brouwer","year":"2014","unstructured":"Brouwer ES, Napravnik S, Eron JJ Jr, et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology. 2014;25:406\u201317.","journal-title":"Epidemiology"},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1473-3099(13)70692-3","volume":"14","author":"B Grinsztejn","year":"2014","unstructured":"Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281\u201390.","journal-title":"Lancet Infect Dis"},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/cid\/civ963","volume":"62","author":"LM Hofstra","year":"2016","unstructured":"Hofstra LM, Sauvageot N, Albert J, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62:655\u201363.","journal-title":"Clin Infect Dis"},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/QAD.0000000000000767","volume":"29","author":"AN Phillips","year":"2015","unstructured":"Phillips AN, Cambiano V, Miners A, et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Aids. 2015;29:1855\u201362.","journal-title":"Aids"},{"key":"1248_CR13","first-page":"45","volume":"142","author":"M Stoll","year":"2000","unstructured":"Stoll M, Claes C, Schulte E, Korner T, von der Schulenburg JM, Schmidt R. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?]. MMW Fortschr Med. 2000;142:45\u20139.","journal-title":"MMW Fortschr Med"},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","volume":"44","author":"BR Schackman","year":"2006","unstructured":"Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990\u20137.","journal-title":"Med Care"},{"key":"1248_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01.qai.0000243090.32866.4e","volume":"43","author":"AB Hutchinson","year":"2006","unstructured":"Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Def Syndrom. 1999;2006; 43:451\u20137.","journal-title":"J Acquir Immune Def Syndrom. 1999"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795\u2013807.","journal-title":"N Engl J Med"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"The TEMPRANO ANRS 12136 Study Group","year":"2015","unstructured":"The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808\u201322.","journal-title":"N Engl J Med"},{"key":"1248_CR18","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. US-Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf\n                    \n                  . Accessed January 2018."},{"key":"1248_CR19","unstructured":"Waters L, Ahmed N, Angus B, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). \n                    http:\/\/www.bhiva.org\/documents\/Guidelines\/Treatment\/2016\/treatment-guidelines-2016-interim-update.pdf\n                    \n                  . Accessed Oct 2017."},{"key":"1248_CR20","unstructured":"EACS. European Guidelines for treatment of HIV-positive adults in Europe 8.0. \n                    http:\/\/www.eacsociety.org\/files\/guidelines_8.0-english-revised_20160610.pdf\n                    \n                  . Accessed Oct 017."},{"key":"1248_CR21","unstructured":"Deutsche AIDS-Gesellschaft, \u00d6sterreichische. AIDS-Gesellschaft. Deutsch -\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. \n                    http:\/\/www.daignet.de\/site-content\/hiv-therapie\/leitlinien-1\n                    \n                  . Accessed Oct 2017."},{"key":"1248_CR22","unstructured":"Deutsche AIDSG. Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2014."},{"key":"1248_CR23","unstructured":"Deutsche AIDS-Gesellschaft, \u00d6sterreichische. AIDS-Gesellschaft. Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2012."},{"key":"1248_CR24","unstructured":"Deutsche AIDS-Gesellschaft, \u00d6sterreichische. AIDS-Gesellschaft. Deutsch -\u00d6sterreichische Leitlinien zur Therapie der HIV-Infektion 2010, 2010."},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1468-1293.2010.00879.x","volume":"12","author":"J Batzing-Feigenbaum","year":"2011","unstructured":"Batzing-Feigenbaum J, Kollan C, Kuhne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, Hamouda O. Cohort profile: the German ClinSurv HIV project\u2013a multicentre open clinical cohort study supplementing national HIV surveillance. HIV Med. 2011;12:269\u201378.","journal-title":"HIV Med"},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00042560-199903010-00002","volume":"20","author":"IC Marschner","year":"1999","unstructured":"Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Def Syndrom Hum Retrovirol. 1999;20:220\u20137.","journal-title":"J Acquir Immune Def Syndrom Hum Retrovirol"},{"key":"1248_CR27","unstructured":"Deutsche AIDS-Gesellschaft. \u00d6sterreichische AIDS-Gesellschaft. Deutsch -\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2002. Dtsch Med Wochenschr 2003; (128): S7-S18."},{"key":"1248_CR28","unstructured":"Deutsche AIDS-Gesellschaft, \u00d6sterreichische. AIDS-Gesellschaft. Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2008. 2008."},{"key":"1248_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/opo.12131","volume":"34","author":"RA Armstrong","year":"2014","unstructured":"Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502\u20138.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1248_CR30","first-page":"1","volume":"41","author":"Centers for Disease Control and Prevention","year":"1993","unstructured":"Centers for Disease Control and Prevention. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommend Rep Morbid Mortal Week Rep Recommend Rep 1992. 1993;41:1\u201319.","journal-title":"MMWR Recommend Rep Morbid Mortal Week Rep Recommend Rep 1992"},{"key":"1248_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12889-015-1598-4","volume":"15","author":"D Schmidt","year":"2015","unstructured":"Schmidt D, Kollan C, Stoll M, et al. From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany. BMC Public Health. 2015;15:252.","journal-title":"BMC Public Health"},{"key":"1248_CR32","unstructured":"INSIGHT START Study Group. Strategic timing of antiretroviral treatment (START) study primary results. In: 8th IAS conference on HIV pathogenesis treatment and prevention. Vancouver, Canada, 2015."},{"key":"1248_CR33","unstructured":"Danel C, Moh R, Gabillard D, et al. Early ART and IPT in HIV-infected African adults with high CD4 Count (Temprano Trial). Conference on retroviruses and opportunistic infections. Seattle, WA, USA, 2015."},{"key":"1248_CR34","doi-asserted-by":"crossref","unstructured":"Stecher M, Chaillon A, Eis-Hubinger AM, et al. Pre treatment HIV-1 drug resistance in transmission clusters of the Cologne-Bonn Region, Germany. Clin Microbiol Infect 2018.","DOI":"10.1093\/ofid\/ofy210.1116"},{"key":"1248_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12879-015-0913-0","volume":"15","author":"P Azar","year":"2015","unstructured":"Azar P, Wood E, Nguyen P, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193.","journal-title":"BMC Infect Dis"},{"key":"1248_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/QAI.0b013e31815767d6","volume":"46","author":"JH Arnsten","year":"2007","unstructured":"Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Def Syndrom 1999;2007; 46:64\u201371.","journal-title":"J Acquir Immune Def Syndrom 1999"},{"key":"1248_CR37","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/09540121.2015.1114992","volume":"27","author":"K Bolsewicz","year":"2015","unstructured":"Bolsewicz K, Debattista J, Vallely A, Whittaker A, Fitzgerald L. Factors associated with antiretroviral treatment uptake and adherence: a review. Perspectives from Australia, Canada, and the United Kingdom. AIDS Care. 2015;27:1429\u201338.","journal-title":"AIDS Care"},{"key":"1248_CR38","first-page":"63","volume":"3","author":"P Rebolledo","year":"2011","unstructured":"Rebolledo P, Kourbatova E, Rothenberg R, del Rio C. Factors associated with utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, Georgia. J AIDS HIV Res (Online). 2011;3:63\u201370.","journal-title":"J AIDS HIV Res (Online)"},{"key":"1248_CR39","unstructured":"Robert-Koch-Institut. Epidemiologisches Bulletin 45, page 476\u2013483. \n                    http:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2015\/Ausgaben\/45_15.pdf?__blob=publicationFile\n                    \n                  . Accessed Jun 2017."},{"key":"1248_CR40","unstructured":"Vourli G, Pharris A, Cazein F, et al. Assessing the representativeness of European HIV cohort participants as compared to HIV surveillance data. In: Control ECfDPa. HepHIV. Malta, 2017."}],"updated-by":[{"DOI":"10.1007\/s15010-019-01281-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-018-1248-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1248-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1248-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T19:24:59Z","timestamp":1573241099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-018-1248-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s15010-018-1248-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the cooperating partners of the ClinSurv HIV cohort were not listed in the acknowledgements. The correct paragraph appears below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study is a project within the TP-HIV by the German Centre for Infection Research (DZIF) (NCT02149004). We declare that all authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}